Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer

A.-R. Hanauske,K. Weigang Koehler,E. Yilmaz,T. Graefe,B. Kuenen,Donald Thornton,Michael Lahn,Christelle Darstein,Luna Musib,G. Guiseppe

Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer

2006

A.-R. Hanauske
K. Weigang Koehler
E. Yilmaz
T. Graefe
B. Kuenen
Donald Thornton
Michael Lahn
Christelle Darstein
Luna Musib
G. Guiseppe

2047 Background: Enzastaurin, an orally administered potent PKC inhibitor, is an anti-angiogenic agent that also suppresses PI3K/AKT to inhibit tumor cell proliferation and induce tumor cell death....

Keywords:

Pemetrexed
Enzastaurin
Cancer research
Cancer
Medicine
Pharmacokinetics
pharmacokinetic interaction
Protein kinase C
Protein kinase B
Pathology
in patient
PI3K/AKT/mTOR pathway

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations